UNSPSC 51111623: Amonafide

This classification denotes a topoisomerase-ii inhibitor and intercalating agent with the molecular formula C16H17N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q8D39N37L, chemically known as 3-amino-n-(2-(dimethylamino)ethyl)-1,8-naphthalindicarboximid but generally known as amonafide, which bears US NIH Compound Identifier 50515. Amonafide most often comes in base and dihydrochloride forms.

UNSPSC 51111623 Amonafide, a Commodity code, encompasses pharmaceutical products sourced through state and local health agency procurement channels. State and local governments buy amonafide — a chemotherapy agent — primarily through health department formularies, hospital systems, and Medicaid pharmacy benefit programs that manage oncology drug inventories and therapeutic protocols. The code sees activity centered in state health agencies and Medicaid-administering departments that establish direct or indirect procurement relationships with pharmaceutical manufacturers and wholesalers to supply oncology formularies to public hospitals, safety-net clinics, and covered beneficiaries.

The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence regarding direct-to-manufacturer prescription programs that would enable state pharmacy benefit programs to establish relationships outside traditional pharmacy benefit manager (PBM) and group purchasing organization (GPO) channels. The RFI solicits vendor experience with direct contracting for self-insured health plans and state agencies, flexibility to negotiate net pricing models, and capacity to implement value-based agreements. Texas HHS framed this as a preliminary market-intelligence phase preceding a formal RFP; no award values, budgets, or response timeline beyond the April 3, 2026 due date are specified. The code shows limited recent activity in state and local procurement records, with the Texas RFI representing the sole documented solicitation in the current opportunity set.